Phase III study of gefitinib (G) versus gefitinib plus carboplatin plus pemetrexed (GCP) as first-line treatment for patients (pts) with advanced non-small cell lung cancer (NSCLC) with EGFR mutations (NEJ009)

被引：0
|
作者：
Seike, M. [1 ]
Inoue, A. [2 ]
Sugawara, S. [3 ]
Morita, S. [4 ]
Hosomi, Y. [5 ]
Ikeda, S. [6 ]
Watanabe, K. [7 ]
Takahashi, K. [8 ]
Fujita, Y. [9 ]
Harada, T. [10 ]
Minato, K. [11 ]
Takamura, K. [12 ]
Kobayashi, K. [13 ]
Nukiwa, T. [14 ]
机构：
[1] Nippon Med Sch, Dept Pulm Med & Oncol, Tokyo, Japan
[2] Tohoku Univ, Sch Med, Dept Palliat Med, Sendai, Miyagi, Japan
[3] Sendai Kousei Hosp, Pulm Med, Sendai, Miyagi, Japan
[4] Kyoto Univ, Grad Sch Med, Biomed Stat & Bioinformat, Kyoto, Japan
[5] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Dept Thorac Oncol & Resp Med, Tokyo, Japan
[6] Cardiovasc & Resp Ctr, Div Resp Med, Yokohama, Kanagawa, Japan
[7] Miyagi Canc Ctr, Dept Resp Med, Natori, Miyagi, Japan
[8] Juntendo Univ, Grad Sch Med, Dept Resp Med, Tokyo, Japan
[9] Asahikawa Med Ctr, Resp Med, Asahikawa, Hokkaido, Japan
[10] JCHO Hokkaido Hosp, Dept Pulm Med, Sapporo, Hokkaido, Japan
[11] Gunma Prefectural Canc Ctr, Dept Pulm Med, Ota, Japan
[12] Obihiro Kosei Gen Hosp, Dept Med 1, Obihiro, Hokkaido, Japan
[13] Saitama Med Univ, Int Med Ctr, Dept Pulm Med, Saitama, Japan
[14] Tohoku Univ, Sendai, Miyagi, Japan
来源：
ANNALS OF ONCOLOGY | 2018年 / 29卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1382PD
引用
收藏
页码：496 / 496
页数：1
相关论文
共 50 条
  • [21] Phase II study of meloxicam with carboplatin plus docetaxel in first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
    Ishida, T.
    Kanazawa, K.
    Oizumi, H.
    Yokouchi, H.
    Yamazaki, K.
    Akie, K.
    Sukoh, N.
    Harada, M.
    Munakata, M.
    Isobe, H.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [22] Dacomitinib Versus Gefitinib for First-Line Treatment of Advanced EGFR plus NSCLC in Japanese Patients (ARCHER 1050)
    Nakagawa, K.
    Ohyanagi, F.
    Kato, T.
    Takahashi, T.
    Kaneda, H.
    Nogami, N.
    Niho, S.
    Yamamoto, N.
    Fujita, Y.
    Zhang, H.
    Sbar, E.
    Wang, H.
    Linke, R.
    Tsuji, F.
    Mok, T.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (11) : S2229 - S2230
  • [23] Phase III randomized trial comparing gefitinib to gefitinib with pemetrexed-carboplatin chemotherapy in patients with advanced untreated EGFR mutant non-small cell lung cancer (gef vs gef plus C).
    Noronha, Vanita
    Joshi, Amit
    Patil, Vijay Maruti
    Chougule, Anuradha
    Mahajan, Abhishek
    Janu, Amit
    Purandare, Nilendu
    Kumar, Rajiv
    More, Sucheta
    Goud, Supriya
    Kadam, Nandkumar
    Daware, Nilesh
    Shah, Srushti
    Yadav, Akanksha
    Dutt, Amit
    Trivedi, Vaishakhi
    Behel, Vichitra
    Banavali, Shripad Dinanath
    Prabhash, Kumar
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Anlotinib with gefitinib as first-line therapy in advanced non-small cell lung cancer harboring EGFR mutations: A phase II study
    Ji, Y.
    Wang, X.
    Lou, Z.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S979 - S979
  • [25] Phase II study of a combination regimen of gefitinib and pemetrexed as first-line treatment in patients with advanced non-small cell lung cancer harboring a sensitive EGFR mutation
    Yoshimura, Naruo
    Kudoh, Shinzoh
    Mitsuoka, Shigeki
    Yoshimoto, Naoki
    Oka, Takako
    Nakai, Toshiyuki
    Suzumira, Tomohiro
    Matusura, Kuniomi
    Tochino, Yoshihiro
    Asai, Kazuhisa
    Kimura, Tatsuo
    Kawaguchi, Tomoya
    Hirata, Kazuto
    [J]. LUNG CANCER, 2015, 90 (01) : 65 - 70
  • [26] First-line treatment of EGFR mutation-positive non-small cell lung cancer (NSCLC) by gefitinib
    Moiseyenko, V.
    Procenko, S. A.
    Levchenko, E. V.
    Barchuk, A. S.
    Matsko, D. E.
    Moiseyenko, F. V.
    Ivantsov, A. O.
    Iyevleva, A. G.
    Mitiushkina, N. V.
    Imyanitov, E. N.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [27] PEMETREXED AND CARBOPLATIN VERSUS DOCETAXEL AND CARBOPLATIN AS FIRST-LINE TREATMENT FOR PATIENTS WITH ADVANCED, NON-SQUAMOUS, NON-SMALL CELL LUNG CANCER (NSCLC)
    Ganju, Vinod
    Pereira, Jose
    Kim, Joo-Hang
    Magallanes, Manuel
    Lee, Dae-Ho
    Wang, Jie
    Martinez, Luis
    Barraclough, Helen
    Van Kooten, Maximiliano
    Orlando, Mauro
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S417 - S418
  • [28] Elderly subset analysis of randomized phase III study comparing pemetrexed plus carboplatin with docetaxel plus carboplatin as first-line treatment for patients with locally advanced or metastatic non-small cell lung cancer
    Pereira J.R.
    Cheng R.
    Orlando M.
    Kim J.-H.
    Barraclough H.
    [J]. Drugs in R&D, 2013, 13 (4) : 289 - 296
  • [29] Pemetrexed/carboplatin plus gefitinib as a first-line treatment for EGFR-mutant advanced nonsmall cell lung cancer: a Bayesian network meta-analysis
    Zhang, Zhonghan
    Zeng, Kangmei
    Zhao, Shen
    Zhao, Yuanyuan
    Hou, Xue
    Luo, Fan
    Lu, Feiteng
    Zhang, Yaxiong
    Zhou, Ting
    Ma, Yuxiang
    Yang, Yunpeng
    Fang, Wenfeng
    Huang, Yan
    Zhang, Li
    Zhao, Hongyun
    [J]. THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2019, 11
  • [30] A phase II study of first-line single agent of gefitinib in patients (pts) with stage IV non-small cell lung cancer (NSCLC).
    Suzuki, R
    Hasegawa, Y
    Baba, K
    Saka, H
    Saito, H
    Taniguchi, H
    Yamamoto, M
    Matsumoto, S
    Kato, K
    Shimokata, K
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 640S - 640S
12345